



Bal Pharma Limited

CIN # L85110KA1987PLC008368

13.08.2015

To,
Manager-Listing
National Stock Exchange of India Ltd
Mumbai.

Dear Sir,

Sub : Out Come of the Board Meeting.

As already informed to the exchanges, Board of Directors of the Company has met today and *inter alia* transacted the following business,

1. Taken on record and approved the Un-audited financial results of the Company for the quarter ended 30.06.2015. A copy of the approved financial results along with the report on the limited review conducted by the statutory auditors of the Company is enclosed with this intimation.
2. Convened 28th Annual General Meeting of the Company on 22nd September 2015 at 11.30 AM.
3. Decided to close the Register of Members and Share Transfer Books of the Company from 18th September 2015 to 22nd September 2015 (both days inclusive).
4. Appointed Mr.Sanjay Kumar Agarwal as Company Secretary and Compliance officer of the Company. He is also designated as Deputy General Manager-Finance & CFO of the Company.

Please take our intimation on record.

For Bal Pharma Limited


Shailesh Siroya
Managing Director



Intertek



014

CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bangalore - 560 052. India
Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58

Email : balpharma@vsnl.com Website : www.balpharma.com

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bangalore - 560 099. Ph: 41570813 / 19 Fax: 41570820



BAL PHARMA LIMITED
 Regd. Office: 21-22 Bommasandra Industrial Area, Anekal Taluq, Bangalore 560 099
STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2015
 CIN: L85110KA1987PLC008368, Phone: 080 41379500, Email: secretaria@balpharma.com, url: www.balpharma.com

Sr. No.	Particulars	STANDALONE				(Rs in Lakhs)		
		Quarter Ended		Year Ended	CONSOLIDATED		Year Ended	
		30 Jun 15	31 Mar 15	30 Jun 14	31 Mar 15	Quarter ended	Year Ended	
		Unaudited	Audited	Unaudited	Audited	30 Jun 15 Unaudited	31 Mar 15 Audited	31 Mar 15 Audited
PART I								
1	Income from Operations							
	a) Net Sales/Income from operations (Net of Excise Duty)	4,052.59	4,993.90	4,144.60	18,245.70	4,055.24	4,995.32	18,248.43
	b) Other Operating Income	74.13	209.83	89.43	467.30	74.13	209.83	467.30
	Total Income from Operations (net)	4,126.72	5,203.73	4,234.03	18,713.00	4,129.37	5,205.15	18,715.73
2	Expenses							
	a) Consumption of Raw Materials/ Packing Material	2,138.16	2,675.88	2,264.55	9,611.71	2,134.16	2,675.88	9,611.71
	b) Purchase of Stock in Trade	139.95	216.41	106.50	622.89	141.26	216.48	627.69
	c) Increase/decrease in stock in trade and WIP	(183.65)	(128.74)	(192.75)	(314.68)	(183.65)	(128.73)	(319.03)
	d) Employee Cost	790.41	834.60	764.33	3,196.24	805.57	850.22	3,224.27
	e) Depreciation and amortisation expenses	159.57	357.69	112.14	700.35	160.36	358.47	702.33
	f) Other Expenditure	902.68	1,108.76	890.95	3,844.23	911.14	1,115.70	3,860.48
	g) Total	3,947.12	5,064.60	3,945.72	17,660.74	3,972.84	5,088.02	17,707.45
3	Profit from Operations before other Income, finance costs and							
	Exceptional items(1-2)	179.60	139.13	288.31	1,052.26	156.53	117.13	1,008.28
4	Other Income	16.54	69.39	6.03	119.48	16.54	67.32	117.41
5	Profit before finance cost and Exceptional items (3+4)	196.14	208.52	294.34	1,171.74	173.07	184.45	1,125.69
6	Finance Costs	130.02	144.49	162.73	651.62	130.03	144.50	651.64
7	Profit after finance cost but before Exceptional items	66.12	64.03	131.61	520.12	43.04	39.95	474.05
8	Exceptional items	-	-	-	-	0	-	-
9	Profit/Loss from ordinary activities Before Tax (7-8)	66.12	64.03	131.61	520.12	43.04	39.95	474.05
10	Tax expenses	17.86	8.36	33.20	117.84	17.86	8.49	118.74
11	Net Profit / Loss from ordinary Activities after Tax	48.26	55.67	98.41	402.28	25.18	31.46	355.31
12	Extra ordinary items	-	-	-	-	0	-	-
13	Net Profit / Loss for the period	48.26	55.67	98.41	402.28	25.18	31.46	355.31
14	Minority interest					(1.92)	(2.93)	(7.48)
15	Net Profit / Loss after taxes and minority interest	48.26	55.67	98.41	402.28	27.10	34.38	362.79
14	Paid-up Equity Share capital(face value of Rs 10 each)	1,287.24	1,287.24	1,287.24	1,287.24	1,287.24	1,287.24	1,287.24
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year							
16	Earnings Per Share (of Rs 10 each) (Quarterly EPS not annualised)							
	a) Basic In Rs	0.37	0.43	0.78	3.14	0.21	0.26	2.83
	b) Diluted In Rs	0.37	0.43	0.78	3.11	0.21	0.26	2.80

PART II								
A) Particulars of Shareholding								
1) Public shareholding								
-	Number of Shares	65,86,570	65,86,570	65,86,570	65,86,570	65,86,570.0	65,86,570	65,86,570
-	Percentage of shareholding	51.17	51.17	51.17	51.17	51.17%	51.17	51.17
2) Promoters & Promoter group Shareholding								
a) Pledged / Encumbered								
-	Number of Shares	-	-	-	-	-	-	###
-	Percentage of shareholding	-	-	-	-	-	-	###
b) Non-encumbered								
-	Number of Shares	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802
-	Percentage of shares (as a % of total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%	100%
-	Percentage of shareholding (as a % of total share capital of the company)	48.83	48.83	48.83	48.83	48.83%	48.83	48.83

PART III	
B	Quarter ended
Investor Complaints	30.06.2015
Pending at the beginning of the quarter	-
Received during the quarter	4
Disposed of during the quarter	4
Remaining unresolved at the end of the quarter	-

Notes:

- 1 The above unaudited financial results as reviewed by the Audit Committee were approved by the Board of Directors at its meeting held on 13.08.2015
- 2 Statutory auditors have conducted limited review on the unaudited financial results for the quarter ended 30.06.2015
- 3 Previous year figures were regrouped/rearranged to conform to the classification of current year.
- 4 Since there were no subsidiaries as on 30.06.2014, comparative figures were not given for the June 2014 quarter in the consolidated results.
- 5 As the company deals with single product i.e pharmaceuticals, segment wise figures are not furnished.

By order of the Board of Directors
For Bal Pharma Limited

Shailesh Siroya
Managing Director





T D JAIN AND D I SAKARIA

CHARTERED ACCOUNTANTS

CA T.D. JAIN B.Com., F.C.A.
CA DHANPAL I SAKARIA
B.Com., F.C.A.

34, Keshava Nivas, 3rd Floor
First Main, Gandhinagar
Bangalore-560 009
Phone : 22356135, 22356137
Telefax : 080-22356136
E-mail : ostawaljain@gmail.com

LIMITED REVIEW REPORT FOR THE QUARTER ENDED JUNE 30, 2015

To
Board of Directors
Bal Pharma Limited

We have reviewed the results of **Bal Pharma Limited** ("the Company") having its registered office at 21 & 22, Bommasandra Industrial Area, Hosur Road, Bangalore - 560099 for the quarter ended on June 30, 2015 which are in the accompanying 'statement of unaudited financial results for the quarter ended 30 June 2015' (the "statement") except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management but have neither been reviewed nor been audited by us. The statement is the responsibility of the Company's management and has been approved by the Board of Directors/committee of the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the independent auditor of the entity" issued by the Institute Of Chartered Accountants Of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement has not been prepared in all material respects in accordance with the applicable Accounting Standards" issued under Companies (Accounting Standards) Rules, 2006 which continue to apply as per section 133 of the Companies Act, 2013, read with Rule 7 of Companies (Accounts) Rules, 2014, and other recognized accounting practices and policies generally accepted in India and has not disclosed the information required to be disclosed in terms of Clause 41, of the Listing Agreements with Stock Exchanges including the manner in which it is to be disclosed, or that it contains any material misstatements.

For M/s T D JAIN AND D I SAKARIA
Chartered Accountants

DHANPAL I SAKARIA
Partner
M No 213666

Place: Bengaluru
Date: 13 August 2015